Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Focused ultrasound and microbubbles targeting alpha-synuclein pathology-related dementia (FUMA)

Project description

A sound approach to slowing Parkinson’s dementia

More than half of patients diagnosed with Parkinson’s disease develop dementia as the condition progresses. This cognitive decline is linked to toxic protein aggregates in the brain and impaired microglial activity (the cells responsible for clearing such waste). The EU-funded FUMA project will investigate whether focused ultrasound with microbubbles can help. This non-invasive technique temporarily opens the blood–brain barrier, allowing the brain to clear harmful proteins and restore synaptic health. In mouse models of Parkinson’s dementia, FUMA will test whether this method improves cognition and slows neurodegeneration, while also identifying imaging biomarkers and molecular pathways. If successful, it could lay the groundwork for a new, safer therapy for Parkinson’s-related dementia.

Objective

Over half of Parkinson Disease patients develop cortical dysfunctions leading to Parkinson Disease Dementia (PDD). The cognitive changes are primarily driven by pathological alpha-synuclein (a-syn) protein aggregates with secondary synaptic dysfunctions in the cortex. Microglia plays a key role in synapse maintenance and clearance of aggregated a-syn proteins, however, this is impaired in PD.
Low intensity focused ultrasound (FUS) combined with intravenous microbubbles (MB) can non-invasively increase the permeability of the blood-brain barrier, resulting in a transient and controlled entry of blood-born substances. In animal models of Alzheimer disease, FUS-MB treatments increase microglial-mediated clearance of extra- and intracellular protein aggregates and improve synapse health. In small patient cohorts in the clinic, FUS-MB treatments are safe and results suggest decreased levels of pathological proteins in Alzheimer disease patients.
HYPOTHESIS: FUS-MB applications targeted to the cortex promote cortical a-syn clearance and synapse maintenance which can prevent or slow the development of dementia in PD.
In a mouse model of PDD we will determine the ability of FUS-MB treatment to increase microglial-mediated clearance of a-syn, maintain synapse health, and inhibit the development of cognitive dysfunctions. In addition, we aim to evaluate non-invasive positron emission tomography and magnetic resonance imaging as biomarkers of the effects of FUS-MB treatment. Finally, we will investigate the underlying pathway of potentially beneficial effects of FUS-MB treatments by measuring changes in specific pathways of interest as well as perform an unbiased screen for novel targets.
Both the researcher and supervisor have a background in Parkinson disease research. The researcher brings expertise in FUS-MB treatments of mouse models and the supervisor is an expert in preclinical and clinical neuromodulation, the latter with FUS.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-TMA-MSCA-PF-EF - HORIZON TMA MSCA Postdoctoral Fellowships - European Fellowships

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-MSCA-2022-PF-01

See all projects funded under this call

Coordinator

AARHUS UNIVERSITET
Net EU contribution
€ 230 774,40
Address
NORDRE RINGGADE 1
8000 Aarhus C
Denmark
Region
Danmark Midtjylland Østjylland
Activity type
Higher or Secondary Education Establishments
Links
Total cost
No data